Bevacizumab biosimilar - Biocad

Drug Profile

Bevacizumab biosimilar - Biocad

Alternative Names: BCD-021

Latest Information Update: 06 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biocad
  • Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Non-small cell lung cancer

Most Recent Events

  • 30 Mar 2016 Biocad terminates phase I trial in Wet age-related macular degeneration in Russia (NCT02450981)
  • 30 Mar 2016 Biocad terminates the GALATIR trial in Wet age-related macular degeneration in Brazil and Russia (NCT02036723)
  • 09 Dec 2015 Registered for Non-small cell lung cancer (Combination therapy, Late-stage disease) in Sri Lanka (IV) after December 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top